Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00388674 · ClinicalTrials.gov registry record
Study of Entecavir in Patients With Chronic Hepatitis B Virus (HBV) Infection
A clinical trial, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- 12,522
- Enrollment target
NCT00388674: Completed study, sponsored by Bristol-Myers Squibb.
NCT00388674 is a clinical trial that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 12,522 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00388674 has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- 12,522 participants
- Enrollment target
Study Summary
The purpose of this study is to prospectively assess the long-term outcomes (benefits and risks) associated with entecavir (ETV) therapy as compared to other antivirals approved for the treatment of chronic HBV infection. For the China substudy, patients randomized to entecavir will have safety and efficacy assessments performed during the first year of the study.
Primary Outcome
The number of participants with Overall Malignant Neoplasm, as adjudicated by Events Adjudication Committee (EAC)
Interventions
- DRUG entecavir
- DRUG Other anti-HBV medication
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12,522 participants |
| Start Date | 2006-12-18 |
| Est. Completion | 2016-10-26 |
What the finished NCT00388674 record still lists
NCT00388674 is an observational study that tracks outcomes without assigning an intervention. Its 12,522 participants enrollment target places it among the larger protocols in the corpus.
The record links to 0 conditions, and to 2 interventions - of which entecavir is the first listed.
NCT00388674 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00388674 about?
NCT00388674 is a clinical study titled "Study of Entecavir in Patients With Chronic Hepatitis B Virus (HBV) Infection". The purpose of this study is to prospectively assess the long-term outcomes (benefits and risks) associated with entecavir (ETV) therapy as compared to other antivirals approved for the treatment of chronic HBV infection. For the China substudy, patients randomized to entecavir will have safety and ...
What is the current status of trial NCT00388674?
This trial is currently completed. The enrollment target is 12,522 participants. The study started on 2006-12-18. Estimated completion is 2016-10-26.
What interventions are being tested in trial NCT00388674?
The interventions under investigation include: entecavir (DRUG), Other anti-HBV medication (DRUG).
Who is sponsoring clinical trial NCT00388674?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04888832 · 12,500 participants · NA
The Effect of Work Requirements in SNAP in Virginia
- NCT05452941 · 12,500 participants
A Study to Learn About How 20-Valent Pneumococcal Conjugate Vaccine Works in a Real-world Setting
- NCT07069556 · 12,500 participants
ColoSense Post-Approval Study
- NCT07037433 · 12,800 participants · Phase 3
Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI